Medicalsystem Biotechnology Valuation

Is 300439 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300439 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300439 (CN¥11.54) is trading above our estimate of fair value (CN¥5.76)

Significantly Below Fair Value: 300439 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300439?

Key metric: As 300439 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300439. This is calculated by dividing 300439's market cap by their current earnings.
What is 300439's PE Ratio?
PE Ratio	17.7x
Earnings	CN¥250.96m
Market Cap	CN¥4.43b

300439 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2x
Enterprise Value/EBITDA	11x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 300439's PE Ratio compare to its peers?

The above table shows the PE ratio for 300439 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	91.5x
603387 Getein Biotech	18x	n/a	CN¥4.6b
300238 Guanhao BiotechLtd	196.9x	n/a	CN¥3.5b
300653 Yantai Zhenghai Biotechnology	22.9x	15.0%	CN¥3.8b
688293 Shanghai OPM Biosciences	128.3x	60.0%	CN¥4.9b
300439 Medicalsystem Biotechnology	17.7x	n/a	CN¥4.4b

Price-To-Earnings vs Peers: 300439 is good value based on its Price-To-Earnings Ratio (17.7x) compared to the peer average (91.5x).

Price to Earnings Ratio vs Industry

How does 300439's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 300439 is good value based on its Price-To-Earnings Ratio (17.7x) compared to the CN Biotechs industry average (35.5x).

Price to Earnings Ratio vs Fair Ratio

What is 300439's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300439 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	17.7x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 300439's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.31

-1.4%

-24.4%

Hunan Jiudian Pharmaceutical

CN¥11.5b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.30

1.8%

13.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.59

-2.4%

12.8%